Hercules Capital Enters into $50MM Term Loan Agreement with Alladapt Immunotherapeutics
Alladapt Immunotherapeutics, a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, entered into a term loan agreement for up to $50 million with Hercules Capital.